IP and Patent Strategy for Advanced Therapies on October 28-29, 2025 in Boston, United States

Stay ahead in an era where advanced therapies are transforming medicine-and redefining how innovation must be protected. The IP and Patent Strategy for Advanced Therapies Summit 2025 is the only event dedicated to shaping holistic, forward-looking IP strategies exclusively for cell, gene, and next-generation treatments.

As more complex therapies move through development pipelines, traditional patent approaches fall short. This summit goes beyond technical tactics to tackle strategic decisions across the full patent life cycle, with a special emphasis on early-stage patentability, freedom to operate, and the use of AI-driven tools to uncover opportunity.

Against a backdrop of rapidly evolving regulations, patent cliffs, and landmark legal battles, now is the moment to rethink how you safeguard commercial potential and secure market advantage. Join top IP leaders to benchmark your approach and build the resilient strategy these therapies demand.

URLs:

Tickets: https://go.evvnt.com/3157041-1?pid=10008

Brochure: https://go.evvnt.com/3157041-2?pid=10008

Time: 8:00 AM - 4:00 PM

Prices:

Drug Developer - 2-Day Conference Pass: USD 2999.00,

Academic and Researcher - 2-Day Conference Pass: USD 2599.00,

Law Firm and Solution Provider - 2-Day Conference Pass: USD 3699.00

Speakers: Dhara Patel, Assistant General Counsel, Intellectual Property, BlueRock Therapeutics, Jon Aumais, Formerly Senior Patent Agent, Genentech, Katie Merriman, Executive Director, Intellectual Property, Umoja Biopharma, Raphaël Ognar, President, Chief Executive Officer, Co-Founder and Chairman of the Board, NKILT Therapeutics, William Coppola, Executive Director, Intellectual Property, Celularity, Will Rosellini, President, CytoImmune Therapeutics, Adam Gastonguay, Director, Patent Counsel, Regeneron, Marthe Lindenbergh, Director, Intellectual Property, uniQure, Christina Jordan, Senior Director, Intellectual Property, Tune Therapeutics, Elbert Chiang, Vice President, Intellectual Property, Beam Therapeutics, Jeanne Wilson, Director, Intellectual Property, Intellia Therapeutics, TJ Cradick, Chief Scientific Officer and Principal, Gene Editing Frontiers, Jacob Sherkow, Professor of Law and Medicine, University of Illinois, David Diamond, Vice President and Head of Intellectual Property, Capstan Therapeutics, Kady Bruce, Patent Counsel, BioNTech, Marshall Byrd, Senior Director IP Management, CureVac